Mirvetuximab

Mirvetuximab is a targeted therapy drug used in the treatment of certain types of ovarian cancer. Its full name is mirvetuximab soravtansine-gynx. It is an antibody-drug conjugate, meaning it combines a targeted antibody with a potent chemotherapy drug. The antibody component of mirvetuximab is designed to specifically bind to a protein called folate receptor alpha (FRα), which is found on the surface of many ovarian cancer cells. Once bound to FRα, the drug conjugate is internalized by the cancer cell. The chemotherapy drug, soravtansine, is then released inside the cell, where it works to kill the cancer cells.

Mirvetuximab soravtansine-gynx is indicated for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Its effectiveness is determined by a companion diagnostic test that measures FRα expression. Clinical trials have demonstrated its efficacy in this patient population, often showing improvements in progression-free survival. Common side effects associated with mirvetuximab can include visual disturbances, nausea, vomiting, abdominal pain, and changes in liver function tests. It is administered intravenously. The development and approval of mirvetuximab represent a significant advancement in personalized medicine for ovarian cancer, offering a treatment option for patients whose tumors express FRα.